The Future of PsA
RheumNow
As we conclude our PsA campaign, Dr. Ogdie shares information about Preventing PsA and Dr. Ritchlin discusses Future Discovery and Targets.
Apr 01, 2022
RX Updates
Secukinumab in patients with Psoriatic Arthritis and Axial Manifestation
Sponsored by Novartis
Secukinumab in patients with Psoriatic Arthritis and Axial Manifestation: results from the double-blind, randomised, phase 3 MAXIMISE trial.
Apr 01, 2022
Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications
Sponsored by Novartis Medical Affairs
The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and postmarketing surveillance data with up to five years of follow-up.
Mar 01, 2022
The Role of a Selective IL-23 p19 inhibitor for Patients with Psoriatic Arthritis
Sponsored by AbbVie Medical Affairs
Psoriatic arthritis is heterogeneous in symptoms and severity. A selective IL-23 p19 inhibitor with a 12-week maintenance dosing interval is approved for adults with active PsA
Feb 01, 2022
Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications
Sponsored by Novartis Medical Affairs
The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and postmarketing surveillance data with up to five years of follow-up.
Feb 01, 2022
The Science of Upadacitinib in Psoriatic Arthritis
Sponsored by AbbVie Medical Affairs
Jan 01, 2022
Comorbidities in axSpA: A Focus on Cardiovascular Features
Sponsored by Novartis Medical Affairs
Patients with axial spondyloarthritis (axSpA) commonly experience cardiovascular (CV) comorbidities. There is a need to holistically assess a patient, including considerations for managing disease activity and understanding the safety profile of available therapies as it relates to comorbidities. Join Marina Magrey, MD as she provides insight on this topic for holistic patient-centered care.
Jan 01, 2022
Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-Related Arthritis (ERA): Current Challenges and Future Outlook
Sponsored by Novartis Medical Affairs
There is a significant burden of disease associated with JPsA and ERA, with patients experiencing structural damage progression, risk of disability, and comorbidities that may persist into adulthood. This presentation led by Hermine Brunner, MD educates on the importance of early recognition and management.
Dec 01, 2021
Women Leaders in Rheumatology: Leadership in a Virtual World
Sponsored by Bristol Myers Squibb and the Bristol Myers Squibb Network of Women (B-NOW)
A moderated panel of prominent female rheumatologists will discuss the challenges and successes in clinical practice and research that they encountered during the COVID-19 pandemic.
Dec 01, 2021
Expert-Selected EULAR 2021 Abstracts
Sponsored by Novartis Medical Affairs
Didn’t have time to join EULAR 2021? Listen to a panel of experts as they present their views on the key abstracts in SpA and Still’s disease.
Aug 01, 2021
Expert Perspectives on Lupus Nephritis
Sponsored by GSK US Medical Affairs
In this disease education video series from GSK, leading rheumatologists and nephrologists share their perspectives on lupus nephritis and reflect upon the gaps that remain in our understanding and management of the disease.
May 03, 2021
Axial Involvement in Spondyloarthritis: A Patient-Centered Exploration
Sponsored by Novartis Medical Affairs
Listen to Ethan Craig, MD, MPH discuss 3 of his patient cases to identify and differentiate axial involvement within the spectrum of spondyloarthritis.
Apr 06, 2021